{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:40:57Z","timestamp":1792071657197,"version":"4.4.0"},"reference-count":30,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,1,25]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment options for chronic pulmonary sarcoidosis are limited in efficacy and by tolerability concerns. Namilumab, an investigational humanised monoclonal antibody inhibiting granulocyte\u2013macrophage colony-stimulating factor, was hypothesised to downregulate the granulomatous response in pulmonary sarcoidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      RESOLVE-Lung was a double-blind, placebo-controlled trial in participants with chronic active pulmonary sarcoidosis on oral corticosteroids (OCS) and\/or immunosuppressive therapies (IST). Participants were randomised (1:1) to receive 150\u2005mg namilumab or placebo\n                      <jats:italic>via<\/jats:italic>\n                      subcutaneous injection every 4\u2005weeks and were required to stop IST and\/or taper OCS. End-points were assessed at week 26. The primary end-point was the proportion of participants with a rescue event, such as disease worsening necessitating treatment. Secondary end-points included safety, lung function assessments and corticosteroid burden. The trial was registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05314517\">NCT05314517<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 209 participants screened, 107 were randomised to receive namilumab (n=53) or placebo (n=54). The proportion of participants with a rescue event was higher for the namilumab group (37.5%) compared with the placebo group (23.5%) (stratified difference 13.6 (90% CI \u22121.5\u201328.7) percentage points; p=0.12). The least squares (LS) mean change from baseline in forced vital capacity % predicted was \u22123.3 (90% CI \u22125.1\u2013\u2009\u22121.5) percentage points for namilumab and \u22122.9 (90% CI \u22124.5\u2013\u2009\u22121.3) percentage points for placebo (LS mean difference \u22120.4 (90% CI \u22122.7\u20132.0) percentage points). The proportion of participants successfully achieving OCS taper was 53.3% for namilumab and 76.9% for placebo (difference \u221219.4 (90% CI \u221247.5\u20138.7) percentage points). Treatment-emergent adverse events were reported in 94% in both groups, most being mild or moderate in severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In participants with chronic active pulmonary sarcoidosis, namilumab did not provide clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01874-2025","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:00:24Z","timestamp":1773327624000},"page":"2501874","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study"],"prefix":"10.1183","volume":"68","author":[{"given":"Bernt","family":"Van Den Blink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder S.","family":"Birring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Mogulkoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Nayci Atis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Guiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-9559","authenticated-orcid":false,"given":"Simon P.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Carmona Porquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3036-6313","authenticated-orcid":false,"given":"Hajira B.","family":"Koeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Arocho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal M.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wijsenbeek-Lourens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore F.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the RESOLVE-Lung investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026070907350958000_68.1.2501874.1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000080"},{"key":"2026070907350958000_68.1.2501874.2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/jcm13030738","article-title":"Treatment of granulomatous inflammation in pulmonary sarcoidosis","volume":"13","author":"Gerke","year":"2024","journal-title":"J Clin Med"},{"key":"2026070907350958000_68.1.2501874.3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0146-2019"},{"key":"2026070907350958000_68.1.2501874.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30615-x"},{"key":"2026070907350958000_68.1.2501874.5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.40420","article-title":"Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor \u03b1 monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis","volume":"70","author":"Burmester","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026070907350958000_68.1.2501874.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071714"},{"key":"2026070907350958000_68.1.2501874.7","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S262566"},{"key":"2026070907350958000_68.1.2501874.8","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1879-x"},{"key":"2026070907350958000_68.1.2501874.9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cyto.2012.12.016","article-title":"Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease","volume":"61","author":"Patterson","year":"2013","journal-title":"Cytokine"},{"key":"2026070907350958000_68.1.2501874.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200803-490OC"},{"key":"2026070907350958000_68.1.2501874.11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1440-1843.1998.tb00130.x","article-title":"Secretion of GM-CSF by inflammatory cells in the lung of patients with sarcoidosis","volume":"3","author":"Itoh","year":"1998","journal-title":"Respirology"},{"key":"2026070907350958000_68.1.2501874.12","doi-asserted-by":"publisher","DOI":"10.1136\/thx.48.12.1230"},{"key":"2026070907350958000_68.1.2501874.13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2213-2600(21)00460-4","article-title":"Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial","volume":"10","author":"Fisher","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026070907350958000_68.1.2501874.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2026070907350958000_68.1.2501874.15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201962"},{"key":"2026070907350958000_68.1.2501874.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(06)80166-6"},{"key":"2026070907350958000_68.1.2501874.17","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.339"},{"key":"2026070907350958000_68.1.2501874.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00198-2023"},{"key":"2026070907350958000_68.1.2501874.19","doi-asserted-by":"crossref","first-page":"108078","DOI":"10.1016\/j.cct.2025.108078","article-title":"Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis","volume":"158","author":"van den Blink","year":"2025","journal-title":"Contemp Clin Trials"},{"key":"2026070907350958000_68.1.2501874.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221865"},{"key":"2026070907350958000_68.1.2501874.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304048"},{"key":"2026070907350958000_68.1.2501874.22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S2213-2600(25)00338-8","article-title":"A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders","volume":"14","author":"Wells","year":"2026","journal-title":"Lancet Respir Med"},{"key":"2026070907350958000_68.1.2501874.23","first-page":"17859","article-title":"WASOG Clinical Trial Endpoint Task Force: Executive Summary","volume":"42","author":"Baughman","year":"2025","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"2026070907350958000_68.1.2501874.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"key":"2026070907350958000_68.1.2501874.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"key":"2026070907350958000_68.1.2501874.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02089-2017"},{"key":"2026070907350958000_68.1.2501874.27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2026070907350958000_68.1.2501874.28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070907350958000_68.1.2501874.29","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202006-607OC"},{"key":"2026070907350958000_68.1.2501874.30","doi-asserted-by":"crossref","first-page":"991783","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01874-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:35:21Z","timestamp":1783607721000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01874-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,9]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/13993003.01874-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01874-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}